CLYM

Climb Bio, Inc. - Common Stock (CLYM)

About Climb Bio, Inc. - Common Stock (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$1.42

Daily low

$1.35

Price at open

$1.38

52 Week High

$9.21

52 Week Low

$1.05

Market cap

92.6M

Dividend yield

0.00%

Volume

82,472

Avg. volume

418,958

P/E ratio

-.58

Climb Bio, Inc. - Common Stock News